Gjørup P H, Wessels J, Pedersen E B
Department of Medical Research, Holstebro Hospital, Holstebro, Denmark.
Scand J Clin Lab Invest. 2008;68(5):375-85. doi: 10.1080/00365510701782382.
Obstructive sleep apnoea (OSA) is a risk factor for cardiovascular morbidity and mortality. The mechanism is unknown, but endothelial dysfunction might contribute. We tested the hypothesis that patients with OSA have abnormal nitric oxide (NO) synthesis, which results in an abnormal response in blood pressure, renal hemodynamics, renal tubular function and vasoactive hormones in response to inhibition of the NO synthesis with L-NMMA.
A randomized, placebo-controlled, single-blinded, crossover study was done in 13 OSA patients and 14 controls. We measured changes in systolic and diastolic blood pressure (SBP and DBP), pulse rate, glomerular filtration rate, renal plasma flow, fractional excretion of sodium and lithium and plasma concentrations of vasoactive hormones after injection of L-NMMA and placebo.
L-NMMA induced a significant increase in SBP and DBP in both groups. The placebo-corrected increase in DBP was more pronounced in patients with OSA than in controls (9 (5-11) versus 3 (1-6) mmHg; p=0.01). Endothelin-1 (ET-1) was significantly higher in patients compared with controls (1.1 (1.0-1.3) versus 0.8 (0.7-0.9) pg/mL; p<0.01). In controls, L-NMMA induced a small increase in ET-1, while no changes were seen in patients. The placebo-corrected change in ET-1 was lower in patients compared to controls (-01 (-0.3-0.0) versus 0.1 (0.0-0.1) pg/mL; p=0.04).
Patients with OSA have abnormally increased NO synthesis and an increased unresponsive level of ET-1 in plasma. This might be due to an imbalance between NO synthesis and ET-1 production.
阻塞性睡眠呼吸暂停(OSA)是心血管疾病发病和死亡的一个危险因素。其机制尚不清楚,但内皮功能障碍可能起作用。我们检验了这样一个假设,即OSA患者存在一氧化氮(NO)合成异常,这导致在使用L-NMMA抑制NO合成时,血压、肾血流动力学、肾小管功能和血管活性激素出现异常反应。
对13例OSA患者和14例对照者进行了一项随机、安慰剂对照、单盲、交叉研究。我们在注射L-NMMA和安慰剂后,测量收缩压和舒张压(SBP和DBP)、脉搏率、肾小球滤过率、肾血浆流量、钠和锂的分数排泄以及血管活性激素的血浆浓度变化。
L-NMMA使两组的SBP和DBP均显著升高。与对照组相比,OSA患者经安慰剂校正后的DBP升高更为明显(9(5 - 11)mmHg对3(1 - 6)mmHg;p = 0.01)。患者的内皮素-1(ET-1)水平显著高于对照组(1.1(1.0 - 1.3)pg/mL对0.8(0.7 - 0.9)pg/mL;p < 0.01)。在对照组中,L-NMMA使ET-1略有升高,而患者组未见变化。与对照组相比,患者组经安慰剂校正后的ET-1变化更低(-0.1(-0.3 - 0.0)pg/mL对0.1(0.0 - 0.1)pg/mL;p = 0.04)。
OSA患者的NO合成异常增加,血浆中ET-1的无反应水平升高。这可能是由于NO合成与ET-1产生之间的失衡所致。